2 reports of this reaction
2.9% of all SILICEA reports
#2 most reported adverse reaction
GASTROINTESTINAL DISORDER is the #2 most commonly reported adverse reaction for SILICEA, manufactured by BM Private Limited. There are 2 FDA adverse event reports linking SILICEA to GASTROINTESTINAL DISORDER. This represents approximately 2.9% of all 70 adverse event reports for this drug.
Patients taking SILICEA who experience gastrointestinal disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROINTESTINAL DISORDER is a less commonly reported adverse event for SILICEA, but still significant enough to appear in the safety profile.
In addition to gastrointestinal disorder, the following adverse reactions have been reported for SILICEA:
The following drugs have also been linked to gastrointestinal disorder in FDA adverse event reports:
GASTROINTESTINAL DISORDER has been reported as an adverse event in 2 FDA reports for SILICEA. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROINTESTINAL DISORDER accounts for approximately 2.9% of all adverse event reports for SILICEA, making it one of the most commonly reported side effect.
If you experience gastrointestinal disorder while taking SILICEA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.